The Effect of Subcutaneous Treprostinil on Pulmonary Hypertension Associated with Interstitial Lung Disease

被引：0
|
作者：
Sadushi-Kolici, Roela [1 ]
Shafran, Inbal [2 ]
Prosch, Helmut [3 ]
Skoro-Sajer, Nika [1 ]
Gerges, Christin [1 ]
Lang, Irene [1 ]
机构：
[1] Med Univ Vienna, Cardiol, Internal Med 2, Vienna, Austria
[2] Sheba Med Ctr, Ramat Gan, Israel
[3] Dept Biomed Imaging & Image Guided Therapy, Vienna, Austria
来源：
EUROPEAN RESPIRATORY JOURNAL | 2023年 / 62卷
关键词：
D O I：
10.1183/13993003.congress-2023.PA3487
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] THE ANALYSIS OF INTERSTITIAL LUNG DISEASE WITH PULMONARY HYPERTENSION
    Shen, N.
    RESPIROLOGY, 2011, 16 : 324 - 324
  • [42] Exercise Pulmonary Hypertension in Interstitial Lung Disease
    Henry, K. J.
    Gargani, L.
    Sultan, S.
    Saggar, R.
    Bossone, E.
    Saggar, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [43] Pulmonary hypertension in patients with interstitial lung disease
    Karampitsakos, Theodoros
    Tzouvelekis, Argyrios
    Chrysikos, Serafeim
    Bouros, Demosthenes
    Tsangaris, Iraklis
    Fares, Wassim H.
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2018, 50 : 38 - 46
  • [44] Pulmonary hypertension due to interstitial lung disease
    King, Christopher S.
    Nathan, Steven D.
    CURRENT OPINION IN PULMONARY MEDICINE, 2019, 25 (05) : 459 - 467
  • [45] Subcutaneous Adipose Tissue Is Associated with Presence of Pulmonary Hypertension in Advanced Lung Disease
    Pan, H.
    Anderson, M. R.
    Diamond, J. M.
    Palmer, S. M.
    Oyster, M.
    Torigian, D.
    Porteous, M.
    Arcasoy, S. M.
    Tong, Y.
    Udupa, J.
    Christie, J. D.
    Kawut, S. M.
    Lederer, D. J.
    Al-Naamani, N.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [46] Inhaled treprostinil in group 3 pulmonary hypertension associated with lung disease: results of the INCREASE and PERFECT studies
    Cullivan, Sarah
    Genecand, Leon
    El-Merhie, Natalia
    Mackenzie, Alison
    Lichtblau, Mona
    BREATHE, 2025, 21 (01)
  • [47] Plain language summary of the INCREASE study: inhaled treprostinil (Tyvaso) for the treatment of pulmonary hypertension due to interstitial lung disease
    West, Natalie
    Smoot, Karen
    Patzlaff, Natalie
    Miceli, Melissa
    Waxman, Aaron
    FUTURE CARDIOLOGY, 2023, 19 (05) : 229 - 239
  • [48] Safety and tolerability of inhaled treprostinil with phosphodiesterase-5 inhibitors in patients with pulmonary hypertension due to interstitial lung disease
    Zisman, David
    Dubrock, Hilary
    King, Christopher
    Weaver, Sheila
    Nathan, Steven
    Rahaghi, Franck
    Kim, Hyoshin
    Rao, Youlan
    Shen, Eric
    Waxman, Aaron
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [49] Subcutaneous treprostinil: a new treatment for chronic thromboembolic pulmonary hypertension?
    Ghofrani, Hossein-Ardeschir
    LANCET RESPIRATORY MEDICINE, 2019, 7 (03): : 191 - 193
  • [50] Diagnostic Predictors Of Pulmonary Hypertension-Associated Mortality In Interstitial Lung Disease
    Adegunsoye, A.
    Chung, J. H.
    Montner, S.
    Narang, N.
    Lee, C. T.
    Witt, L. J.
    Oldham, J. M.
    Chen, L.
    Hsu, S.
    Bag, R.
    Husain, A.
    Noth, I.
    Vij, R.
    Strek, M. E.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
12345